To explore the effect of vedolizumab in the treatment of ulcerative colitis(UC) and its mechanism of action on mitochondrial autophagy.
A total of 96 patients with UC admitted to our hospital from January 2021 to December 2024 were selected as the research subjects. They were divided into the observation group and the control group by simple sorting random method, with 48 cases in each group. By the end of the study, the two groups had dropped to the observation group with 46 cases and the control group with 45 cases. The control group was treated with mesalazine enteric-coated tablets, while the observation group was added with vedolizumab. The treatment courses for both groups were 8 weeks. After treatment, the clinical efficacy, mitochondrial autophagy, inflammatory factors, intestinal mucosal barrier function and clinical symptom scores of the two groups were compared.
After treatment, the total effective rate of the observation group was higher than that of the control group(82.61% vs 62.22%, P<0.05). After treatment, the levels of PTEN-induced putative kinase(PINK)1 and parkinin in both groups were compared with those before treatment(P<0.05), and those in the observation group were higher than those in the control group(P<0.05). After treatment, the levels of tumor necrosis factor-α, interleukin(IL)-17 and IL-23 in both groups were lower than those before treatment(P<0.05), and those in the observation group were lower than those in the control group(P<0.05). After treatment, the levels of D-lactic acid, diamine oxidase and endothelin in both groups were lower than those before treatment(P<0.05), and those in the observation group were lower than those in the control group(P<0.05). By the end of the treatment, the scores of abdominal pain, diarrhea, mucus and bloody stool, and the total score in the observation group were all lower than those in the control group(P<0.05).
Vedilizumab treatment has a good effect on UC, which can increase the contents of PINK1 and paraquin in patients and reduce the levels of inflammatory factors.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |